News @ a glance
- Several Chinese herbal products may contain toxic aristolochic acid. Wooltorton, Eric // CMAJ: Canadian Medical Association Journal;8/31/2004, Vol. 171 Issue 5, p449
Provides information on aristolochic acid, a naturally occurring herbal toxin that can cause cancer and end-stage kidney failure. Precautions issued by the Health Canada concerning several Chinese herbal products containing aristolochic acid; Discussion on the toxicity of aristolochic acid.
- Clinical practice guidelines for the care and treatment of breast cancer: the management of chronic pain in patients with breast cancer (summary of the 2001 update). Emery, Chris; Gallagher, Romayne; Hugi, Maria; Levine, Mark // CMAJ: Canadian Medical Association Journal;10/30/2001, Vol. 165 Issue 9, p1218
Provides a summary of changes made by Health Canada's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer to the 1998 article 'Clinical practice guidelines for the care and treatment of breast cancer: 10. The management of chronic pain in patients with...
- Canadians re-register simazine. // Splash!;Apr/May2010, p9
The article reports that the Pest Management Regulatory Agency of Health Canada has issued a continued of simazine containing products for sale and use in Canada for the herbicide do not present human health and environmental risks.
- Green tea, mistletoe, and more: Canadians test alternative cancer therapies. Holzman, David // JNCI: Journal of the National Cancer Institute;05/21/97, Vol. 89 Issue 10, p683
Reports that the Canadian Breast Cancer Research Institute, a joint venture of Health Canada and the Canadian Cancer Society, has released a request for applications for research on alternative therapies for breast cancer early on in 1997. Six most popular alternative treatments for breast...
- Clinical practice guidelines for the care and treatment of breast cancer: the management of ductal carcinoma in situ (summary of the 2001 update). Olivotto, Ivo; Levine, Mark // CMAJ: Canadian Medical Association Journal;10/2/2001, Vol. 165 Issue 7, p912
Provides a summary of changes made by Health Canada to its clinical practice guidelines for the care and treatment of breast cancer, with focus on the management of ductal carcinoma in situ, as of 2001. Additional evidence to support the original recommendations which were published in 1998;...
- The staggering cost of illness and injury. Martin, Shelley // CMAJ: Canadian Medical Association Journal;2/4/2003, Vol. 168 Issue 3, p332
Presents a study to evaluate the annual cost to Canadians from illness, injury and premature death. Conducted by Health Canada in 1998; Direct and indirect costs; Lost economic out-put associated with mortality; Costs associated with specific diagnostic categories such as cardiovascular disease...
- The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. // CMAJ: Canadian Medical Association Journal;1998 Supplement 3, Vol. 158, pS1
An introduction is presented which discusses various articles within the issue on topics including a list of members of the Health Canada's Steering Committee on clinical practice guidelines, evidences supporting each guideline, and guidelines on the treatment of breast cancer.
- Pharmacovigilance & Regulatory News. // Reactions Weekly;8/13/2011, Issue 1364, p3
This article reports on the move of Health Canada to warn medical personnel and patients of the risks of male breast cancer associated with the use of finasteride.
- Aortic thrombosis after cisplatin treatment. // Reactions Weekly;Aug2014, Vol. 1513 Issue 1, p2
The article informs on the cases of aortic thrombosis found in cancer patients after the initiation of cisplatin treatment which have been reported to government medicare department of Canada, Health Canada.